UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V.

Core Viewpoint - A securities fraud class action lawsuit has been initiated against uniQure N.V., alleging misrepresentations related to its drug AMT-130, which is under development for Huntington's Disease treatment [5][6]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 [5]. - The allegations include violations of the Securities Exchange Act of 1934 against uniQure and certain senior officers [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file necessary documents by April 13, 2026 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [4]. Group 3: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [7].